Metabolomics and Lipidomics for Studying Metabolic Syndrome: Insights into Cardiovascular Diseases, Type 1 & 2 Diabetes, and Metabolic Dysfunction-Associated Steatotic Liver Disease.

Metabolomics and lipidomics have emerged as tools in understanding the connections of metabolic syndrome (MetS) with cardiovascular diseases (CVD), type 1 and type 2 diabetes (T1D, T2D), and metabolic dysfunction-associated steatotic liver disease (MASLD). This review highlights the applications of these omics approaches in large-scale cohort studies, emphasizing their role in biomarker discovery and disease prediction. Integrating metabolomics and lipidomics has significantly advanced our understanding of MetS pathology by identifying unique metabolic signatures associated with disease progression. However, challenges such as standardizing analytical workflows, data interpretation, and biomarker validation remain critical for translating research findings into clinical practice. Future research should focus on optimizing these methodologies to enhance their clinical utility and address the global burden of MetS-related diseases.

• Publication year

  2024

• Venue

  Physiological Research

• Publication date

  2024-08-30

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.33549/physiolres.935443PMID 39212142PMCID PMC11412346
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Plasma metabolite profile of legume consumption and future risk of type 2 diabetes and cardiovascular disease

  2024cited by this paper
• Xylitol is prothrombotic and associated with cardiovascular risk.

  2024cited by this paper
• Gut microbiome features and metabolites in non-alcoholic fatty liver disease among community-dwelling middle-aged and older adults

  2024cited by this paper
• Hydrophilic Interaction Liquid Chromatography–Hydrogen/Deuterium Exchange–Mass Spectrometry (HILIC-HDX-MS) for Untargeted Metabolomics

  2024cited by this paper
• Current status and future trends of the global burden of MASLD.

  2024cited by this paper
• A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk

  2024cited by this paper
• Association of Nonalcoholic Fatty Liver Disease with Arterial Stiffness and its Metabolomic Profiling in Japanese Community-Dwellers

  2024cited by this paper
• Comparison of NAFLD, MAFLD and MASLD characteristics and mortality outcomes in United States adults

  2024cited by this paper
• The Heart of the World

  2024cited by this paper
• Metabolite signature of diabetes remission in individuals with obesity undergoing weight loss interventions

  2023cited by this paper
• Breaking new ground: MASLD vs. MAFLD—which holds the key for risk stratification?

  2023cited by this paper
• Global Burden of Cardiovascular Diseases and Risks, 1990-2022.

  2023cited by this paper
• Reply: A multi-society delphi consensus statement on new fatty liver disease nomenclature.

  2023cited by this paper
• Low-Resolution or High-Resolution MS for Clinical and Forensic Toxicology: Some Considerations from Two Real Cases

  2023cited by this paper
• Microbe-derived uremic solutes enhance thrombosis potential in the host

  2023cited by this paper
• Erratum to "IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045" [Diabetes Res. Clin. Pract. 183 (2022) 109119].

  2023cited by this paper
• The metabolic potential of inflammatory and insulinaemic dietary patterns and risk of type 2 diabetes

  2023cited by this paper
• Prevalence and Risk Factors of Metabolic Syndrome: A Prospective Study on Cardiovascular Health

  2023cited by this paper
• Clinical and histological features under different nomenclatures of fatty liver disease: NAFLD, MAFLD, MASLD and MetALD.

  2023cited by this paper
• (Re‐)use and (re‐)analysis of publicly available metabolomics data

  2023cited by this paper
• Scaling-up metabolomics: Current state and perspectives

  2023cited by this paper
• Metabolic dysfunction-associated steatotic liver disease (MASLD) definition is better than MAFLD criteria for lean patients with non-alcoholic fatty liver disease (NAFLD).

  2023cited by this paper
• Large-scale lipidomics profiling reveals characteristic lipid signatures associated with an increased cardiovascular risk

  2023cited by this paper
• Large-scale metabolomic profiling and incident non-alcoholic fatty liver disease

  2023cited by this paper
• A multisociety Delphi consensus statement on new fatty liver disease nomenclature

  2023cited by this paper
• LORA, Lipid Over-Representation Analysis Based on Structural Information

  2023cited by this paper
• Comparison between 5 extractions methods in either plasma or serum to determine the optimal extraction and matrix combination for human metabolomics

  2023cited by this paper
• Combining serum metabolomic profiles with traditional risk factors improves 10-year cardiovascular risk prediction in people with type 2 diabetes.

  2023cited by this paper
• Short-Term Stability of Serum and Liver Extracts for Untargeted Metabolomics and Lipidomics

  2023cited by this paper
• Multiplatform Untargeted Metabolomics.

  2023cited by this paper
• Gut Microbiota–Derived Trimethylamine N-Oxide Contributes to Abdominal Aortic Aneurysm Through Inflammatory and Apoptotic Mechanisms

  2023cited by this paper
• Metabolic Syndrome: The Constellation of Co-morbidities, a Global Threat.

  2023cited by this paper
• The artificial sweetener erythritol and cardiovascular event risk

  2023cited by this paper
• The Link between NAFLD and Metabolic Syndrome

  2023cited by this paper
• Optimization of Mobile Phase Modifiers for Fast LC-MS-Based Untargeted Metabolomics and Lipidomics

  2023cited by this paper
• The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review

  2023cited by this paper
• Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles

  2022cited by this paper
• Healthy lifestyle, metabolomics and incident type 2 diabetes in a population-based cohort from Spain

  2022cited by this paper
• Changes in the global, regional, and national burdens of NAFLD from 1990 to 2019: A systematic analysis of the global burden of disease study 2019

  2022cited by this paper
• Good practices and recommendations for using and benchmarking computational metabolomics metabolite annotation tools

  2022cited by this paper
• Healthy lifestyle, plasma metabolites, and risk of cardiovascular disease among individuals with diabetes.

  2022cited by this paper
• Current analytical methods to monitor type 2 diabetes medication in biological samples

  2022cited by this paper
• Toward building mass spectrometry-based metabolomics and lipidomics atlases for biological and clinical research

  2022cited by this paper
• Association between NMR metabolomic signatures of healthy lifestyle and incident coronary artery disease.

  2022cited by this paper
• Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study.

  2022cited by this paper
• Geographic distribution of metabolic syndrome and its components in the general adult population: a meta-analysis of global data from 28 million individuals.

  2022cited by this paper
• Integration of Infant Metabolite, Genetic and Islet Autoimmunity Signatures to Predict Type 1 Diabetes by 6 Years of Age.

  2022cited by this paper
• Guide to Metabolomics Analysis: A Bioinformatics Workflow

  2022cited by this paper
• Deep Lipidomics in Human Plasma: Cardiometabolic Disease Risk and Effect of Dietary Fat Modulation

  2022cited by this paper
• Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease

  2022cited by this paper
• Prediction of Type 1 Diabetes at Birth: Cord Blood Metabolites vs Genetic Risk Score in the Norwegian Mother, Father, and Child Cohort

  2021cited by this paper
• MetaboAnalyst 5.0: narrowing the gap between raw spectra and functional insights

  2021cited by this paper
• IDF diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045.

  2021cited by this paper
• Hydrogen/deuterium exchange mass spectrometry in the world of small molecules.

  2021cited by this paper
• Current state-of-the-art of separation methods used in LC-MS based metabolomics and lipidomics.

  2021cited by this paper
• Mendelian Randomization Analysis Identifies Blood Tyrosine Levels as a Biomarker of Non-Alcoholic Fatty Liver Disease

  2021cited by this paper
• Association of Trimethylamine N-Oxide and Related Metabolites in Plasma and Incident Type 2 Diabetes

  2021cited by this paper
• Association of the odd-chain fatty acid content in lipid groups with type 2 diabetes risk: A targeted analysis of lipidomics data in the EPIC-Potsdam cohort.

  2021cited by this paper
• Mass spectrometry-based metabolomics: a guide for annotation, quantification and best reporting practices

  2021cited by this paper
• DecoID Improves Identification Rates in Metabolomics through Database-Assisted MS/MS Deconvolution

  2021cited by this paper
• Eight key rules for successful data‐dependent acquisition in mass spectrometry‐based metabolomics

  2021cited by this paper
• 1‐Deoxyceramides – Key players in lipotoxicity and progression to type 2 diabetes?

  2021cited by this paper
• A new definition for metabolic associated fatty liver disease: an international expert consensus statement.

  2020cited by this paper
• Discovery of metabolite profiles of metabolic syndrome using untargeted and targeted LC-MS based lipidomics approach.

  2020cited by this paper
• SSizer: Determining the Sample Sufficiency for Comparative Biological Study.

  2020cited by this paper
• A Cardiovascular Disease-Linked Gut Microbial Metabolite Acts via Adrenergic Receptors.

  2020cited by this paper
• Current status of retention time prediction in metabolite identification.

  2020cited by this paper
• Important Considerations for Sample Collection in Metabolomics Studies with a Special Focus on Applications to Liver Functions

  2020cited by this paper
• Prevalence and incidence of type 1 diabetes in the world: a systematic review and meta-analysis

  2020cited by this paper
• Comparison of Full-Scan, Data-Dependent, and Data-Independent Acquisition Modes in Liquid Chromatography-Mass Spectrometry Based Untargeted Metabolomics.

  2020cited by this paper
• A lipidome atlas in MS-DIAL 4

  2020cited by this paper
• Plasma sphingolipids and risk of cardiovascular diseases: a large-scale lipidomic analysis

  2020cited by this paper
• METLIN MS2 molecular standards database: a broad chemical and biological resource

  2020cited by this paper
• Update on LIPID MAPS classification, nomenclature, and shorthand notation for MS-derived lipid structures

  2020cited by this paper
• Assessment of human plasma and urine sample preparation for reproducible and high-throughput UHPLC-MS clinical metabolic phenotyping.

  2020cited by this paper
• The prevalence of pediatric metabolic syndrome—a critical look on the discrepancies between definitions and its clinical importance

  2020cited by this paper
• Ether lipids, sphingolipids and toxic 1‐deoxyceramides as hallmarks for lean and obese type 2 diabetic patients

  2020cited by this paper
• Sample size, power and effect size revisited: simplified and practical approaches in pre-clinical, clinical and laboratory studies

  2020cited by this paper
• Walnut Consumption, Plasma Metabolomics, and Risk of Type 2 Diabetes and Cardiovascular Disease.

  2020cited by this paper
• Ether Lipids and Adipocyte-Derived 1-Deoxyceramides as Hallmarks for Lean and Obese Type 2 Diabetic Patients

  2020cited by this paper
• DecoMetDIA: Deconvolution of Multiplexed MS/MS Spectra for Metabolite Identification in SWATH-MS based Untargeted Metabolomics.

  2019cited by this paper
• Data analysis of MS-based clinical lipidomics studies with crossover design: A tutorial mini-review of statistical methods.

  2019cited by this paper
• From Samples to Insights into Metabolism: Uncovering Biologically Relevant Information in LC-HRMS Metabolomics Data

  2019cited by this paper
• Serum metabolic signatures of coronary and carotid atherosclerosis and subsequent cardiovascular disease

  2019cited by this paper
• Metabolic profiling of adolescent non-alcoholic fatty liver disease

  2019cited by this paper
• Three-phase liquid extraction: a simple and fast method for lipidomic workflows[S]

  2019cited by this paper
• Circulating metabolites and the risk of type 2 diabetes: a prospective study of 11,896 young adults from four Finnish cohorts

  2019cited by this paper
• From mass to metabolite in human untargeted metabolomics: Recent advances in annotation of metabolites applying liquid chromatography-mass spectrometry data

  2019cited by this paper
• Development of a Plasma Screening Panel for Pediatric Nonalcoholic Fatty Liver Disease Using Metabolomics

  2019cited by this paper
• Software Tools and Approaches for Compound Identification of LC-MS/MS Data in Metabolomics

  2018cited by this paper
• Serum metabolomic profile of incident diabetes

  2018cited by this paper
• Untargeted metabolomics identifies trimethyllysine, a TMAO-producing nutrient precursor, as a predictor of incident cardiovascular disease risk.

  2018cited by this paper
• Risk factors and biomarkers of non-alcoholic fatty liver disease: an observational cross-sectional population survey

  2018cited by this paper
• Metabolic profiling of adolescent non-alcoholic fatty liver disease.

  2018cited by this paper
• Obesogenic diets alter metabolism in mice

  2018cited by this paper
• Comparative analysis of creatinine and osmolality as urine normalization strategies in targeted metabolomics for the differential diagnosis of asthma and COPD

  2018cited by this paper
• Guidelines and considerations for the use of system suitability and quality control samples in mass spectrometry assays applied in untargeted clinical metabolomic studies

  2018cited by this paper
• Quality Control and Validation Issues in LC-MS Metabolomics.

  2018cited by this paper
• Quality assurance procedures for mass spectrometry untargeted metabolomics. a review

  2018cited by this paper
• Identification of small molecules using accurate mass MS/MS search.

  2018cited by this paper

• Health Challenges and Frontier Solutions for the Post-80s and Post-90s Generation

  2026cites this paper
• Associated factors and principal pathophysiological mechanisms of type 2 diabetes mellitus

  2025cites this paper
• Serum and Liver Lipidome Following Empagliflozin Administration for Six Months in a Fast Food Diet Mouse Model

  2025cites this paper
• Relationship between Alzheimer's Disease and Type 2 Diabetes: Critical Review On Cellular and Molecular Common Pathogenic Mechanisms.

  2025cites this paper
• Risk Factors for Liver Fibrosis in Patients with Type 2 Diabetes Mellitus and Metabolic Dysfunction–Associated Steatotic Liver Disease in Brazzaville

  2025cites this paper
• Night-to-Day Ratio Specified by 24-hour Blood Pressure Monitoring, Arterial Stiffness and Cardio-Ankle Vascular Index as Predictive Factors of Cardiovascular Risk

  2025cites this paper
• Type 1 diabetes mellitus: the liver’s role, sex-specific outcomes, and advances in disease-modifying therapies - a literature review

  2025cites this paper